Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs

International Journal of Cancer

Volumn 143, Issue 4, 2018, Pages 735-745

  Cuschieri, Kate ^a   Ronco, Guglielmo ^b   Lorincz, Attila ^c   Smith, Laurie ^d   Ogilvie, Gina ^e   Mirabello, Lisa ^f   Carozzi, Francesca ^g   Cubie, Heather ^h   Wentzensen, Nicolas ^f   Snijders, Peter ⁱ   Arbyn, Marc ^j   Monsonego, Joe ^k   Franceschi, Silvia ^l  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f NATIONAL CANCER INSTITUTE   (United States)

^g ISPO   (Italy)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^k Institut du Col   (France)

^l INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

more..

Author keywords

HPV; roadmap; screening; triage

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; PROTEIN P16; WART VIRUS VACCINE; MKI67 PROTEIN, HUMAN;

CANCER GENETICS; CANCER SCREENING; EMERGENCY HEALTH SERVICE; FEMALE; GENOMICS; GENOTYPING TECHNIQUE; HEALTH EDUCATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; NEXT GENERATION SEQUENCING; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR GENE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRAL GENETICS; VIRUS GENOME; WART VIRUS; ALPHAPAPILLOMAVIRUS; COMPLICATION; DNA METHYLATION; EARLY CANCER DIAGNOSIS; EUROPE; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MASS SCREENING; METABOLISM; PATIENT EDUCATION; PROCEDURES; TUMOR SUPPRESSOR GENE; UTERINE CERVIX TUMOR; VIROLOGY;

ALPHAPAPILLOMAVIRUS; DNA METHYLATION; EARLY DETECTION OF CANCER; EUROPE; FEMALE; GENES, P16; GENOTYPE; HUMANS; KI-67 ANTIGEN; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT EDUCATION AS TOPIC; TRIAGE; UTERINE CERVICAL NEOPLASMS;

EID: 85041679825     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.31261     Document Type: Review

References (94)

1. Wentzensen N, Arbyn M, Berkhof J, et al. Eurogin 2016 roadmap: how HPV knowledge is changing screening practice. Int J Cancer 2017; 140:2192–200
2. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol 2015;136:178–82
3. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. WHO 2013. http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf
4. https://www.gov.uk/guidance/cervical-screening-programme-overview
5. Anttila A, Arbyn A, De Vuyst H, et al. eds. European guidelines for quality assurance in cervical cancer screening. Second edition, Supplements. Office for Official Publications of the European Union. Luxembourg 2015;1:22
6. Wentzensen N, Schiffman M, Palmer T, et al. Triage of HPV positive women in cervical cancer screening. J Clin Virol 2016;76 Suppl 1:S49–55
7. Isidean SD, Mayrand MH, Ramanakumar AV, CCCaST Study Group, et al. Comparison of triage strategies for HPV-positive women: Canadian cervical cancer screening trial results. Cancer Epidemiol Biomarkers Prevent 2017;26:923–9
8. Arbyn M, de Sanjose S, Saraiya M, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012;131:1969–82
9. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589–97
10. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78–88
11. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:672–82
12. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32
13. Kotaniemi-Talonen L, Nieminen P, Anttila A, et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005;93:862–7
14. Bergeron C, Giorgi-Rossi P, Cas F, et al. Informed cytology for triaging HPV positive women: sub-study nested in the NTCC randomized controlled trial. J Natl Cancer Inst 2015;107:dju423. doi:10.1093/jnci/dju423
15. Sørbye SW, Suhrke P, Revå BW, et al. Accuracy of cervical cytology: comparison of diagnoses of 100 Pap smears read by four pathologists at three hospitals in Norway. BMC Clin Pathol 2017;17:18
16. Ronco G, Zappa M, Franceschi S, et al. Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms. Eur J Cancer 2016;68:148–55
17. Schiffman M, Yu K, Zuna R, et al. Proof-of-principle study of a novel cervical screening and triage strategy: computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2. Int J Cancer 2017;140:718–25
18. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349–59
19. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113:18–25
20. Arbyn M, Snijders PJ, Meijer CJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect 2015;21:817–26
21. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516–42
22. Schiffman M, Burk RD, Boyle S, et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol 2015;53:52–9
23. Von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papil- lomavirus infections. Eur J Cancer 2002;38:2229–42
24. Tsoumpou I, Arbyn M, Kyrgiou M, et al. Paraskevaidis E p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35:210–20
25. Bergeron C, Ikenberg H, Sideri M, PALMS Study Group, et al. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol 2015;123:373–81
26. Kruse A-J, Baak JPA, Helliesen T, et al. Evaluation of MIB-1-positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1501–7
27. Carozzi F, Gillio-Tos A, Confortini M, NTCC working group, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013;14:168–76
28. Wentzensen N, Fetterman B, Castle PE, et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst 2015;107:djv257
29. INK4a –Ki-67 to define the management of human papillomavirus (HPV)–positive women in cervical cancer screening. Am J Clin Pathol 2016;145:35–45
30. Wright TC, Jr, Behrens CM, Ranger-Moore J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol 2017;144:51–6
31. Stanczuk GA, Baxter GJ, Currie H, et al. Defining optimal triage strategies for hrHPV screen-positive women-an evaluation of HPV 16/18 genotyping, cytology, and p16/Ki-67 cytoimmunochemistry. Cancer Epidemiol Biomarkers Prevent 2017;26:1629–35
32. Wentzensen N, Fetterman B, Tokugawa D, et al. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. Cancer Cytopathol 2014;122:914–20
33. Benevolo M, Allia E, Gustinucci D, New Technologies for Cervical Cancer Screening 2 (NTCC2) Working Group, et al. Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women. Cancer 2017;125:212–20
34. Murphy N, Heffron CC, King B, et al. p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch 2004;445:610–5
35. Wentzensen N, Sherman ME, Schiffman M, et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009;112:293–9
36. Clarke MA, Luhn P, Gage JC, et al. Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. Int J Cancer 2017;141:701–10
37. Mirabello L, Sun C, Ghosh A, et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012;104:556–65
38. Wentzensen N, Sun C, Ghosh A, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012;104:1738–49
39. Lorincz A. The virtues and weaknesses of DNA methylation as a test for cervical cancer prevention. Acta Cytol 2016;60:501–12
40. Hesselink AT, Heideman DAM, Steenbergen RDM, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011;17:2459–65
41. Kalantari M, Osann K, Calleja-Macias IE, et al. Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: considerations for use as biomarkers of the progression of cervical neoplasia. Virology 2014;448:314–21
42. Lorincz AT, Brentnall AR, Scibior-Bentkowska D, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer 2016;138:2745–51
43. Verdoodt F, Jentschke M, Hillemanns P, et al. Reaching women who do not participate in the regular cervical cancer screeningprogramme by offering self-sampling kits: a systematic review and meta-analysisof randomised trials. Eur J Cancer 2015;51:2375–85
44. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;15:172–83
45. Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013;132:2223–36
46. Garcia F, Barker B, Santos C, et al. Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus. Obstet Gynecol 2003;102:266–72
47. Brink AA, Meijer CJ, Wiegerinck MA, et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006;44:2518–23
48. Eijsink JJ, Yang N, Lendvai A, et al. Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol 2011;120:280–3
49. Boers A, Bosgraaf RP, van Leeuwen RW, et al. DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. Br J Cancer 2014;111:1095–101
50. Chang CC, Huang RL, Liao YP, et al. Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm. BMC Cancer 2015;15:418
51. Verhoef VM, Bosgraaf RP, van Kemenade FJ, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014;15:315–22
52. De Strooper LM, Verhoef VM, Berkhof J, Hesselink AT, de Bruin HM, van Kemenade FJ, Bosgraaf RP, Bekkers RL, Massuger LF, Melchers WJ, Steenbergen RD, Snijders PJ, Meijer CJ, Heideman DA. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol 2016;141:341–7
53. Steenbergen RD, Snijders PJ, Heideman DA, et al. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014;14:395–405
54. Cullen M, Boland JF, Schiffman M, et al. Deep sequencing of HPV16 genomes: a new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection. Papilloma Res 2015;1:3–11
55. Mirabello L, Yeager M, Cullen M, Boland JF, Chen Z, Wentzensen N, Zhang X, Yu K, Yang Q, Mitchell J, Roberson D, Bass S, Xiao Y, Burdett L, Raine-Bennett T, Lorey T, Castle PE, Burk RD, Schiffman M. HPV16 sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 women. J Natl Cancer Inst 2016;108:djw100
56. Mirabello L, Yeager M, Yu K, et al. HPV16 E7 genetic conservation is critical to carcinogenesis. Cell 2017;170:1164–74
57. Hildesheim A, Schiffman M, Bromley C, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001;93:315–8
58. Pientong C, Wongwarissara P, Ekalaksananan T, et al. Association of human papillomavirus type 16 long control region mutation and cervical cancer. Virol J 2013;10:30. doi:10.1186/1743-422X-10-30
59. Xi LF, Koutsky LA, Hildesheim A, et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prevent 2007;16:4–10
60. Schiffman M, Rodriguez AC, Chen Z, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 2010;70:3159–69
61. Cornet I, Gheit T, Iannacone MR, et al. HPV16 genetic variation and the development of cervical cancer worldwide. Br J Cancer 2013;108:240–4
62. Gheit T, Cornet I, Clifford GM, et al. Risks for persistence and progression by human papillomavirus Type 16 variant lineages among a population-based sample of Danish women. Cancer Epidemiol Biomarkers Prevent 2011;20:1315–21
63. Zehbe I, Voglino G, Delius H, et al. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 1998;352:1441–2
64. Zuna RE, Moore WE, Shanesmith RP, et al. Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population. Int J Cancer 2009;125:2609–13
65. Sichero L, Ferreira S, Trottier H, et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007;120:1763
66. Berumen J, Ordoñez RM, Lazcano E, et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case–control study. J Natl Cancer Inst 2001;93:1325–30
67. Freitas LB, Chen Z, Muqui EF, et al. Human papillomavirus 16 non-European variants are preferentially associated with high-grade cervical lesions. PLoS ONE 2014;9:e100746
68. Burk RD, Terai M, Gravitt PE, et al. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res 2003;63:7215–20
69. Quint KD, de Koning MNC, van Doorn L-J, et al. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol 2010;117:297–301
70. Rabelo-Santos SH, Villa LL, Derchain SF, et al. Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear. Int J Gynecol Pathol 2006;25:393–7
71. Nicolás-Párraga S, Alemany L, de Sanjosé S, et al. Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma. Int J Cancer 2017;140:2092–100
72. Campbell C, Kafwafwa S, Brown H, et al. Use of thermo-coagulation as an alternative treatment modality in a ‘screen and treat’ programme of cervical screening in rural Malawi. Int J Cancer 2016;139:908–15
73. Cubie HA, Morton D, Kawonga E, et al. Using the cartridge-based GeneXpert® HPV assay to assess HPV prevalence in women attending cervical screening in rural Malawi. J Clin Virol 2017;87:1–4
74. Campos NG, Tsu V, Jeronimo J, et al. Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings. Cancer Med 2017;6:2008–14
75. Santesso N, Mustafa RA, Schuneman HJ, Guideline Support Group, et al. World Health Organisation Guidelines for treatment of cervical intraepithelial neoplasia 2–3 and screen-and-treat strategies to prevent cervical cancer. Int J Gynaecol Obstet 2016;132:252–8
76. Kreimer AR, Rodriguez AC, Hildesheim A, CVT Vaccine Group, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103:1444–51
77. Bosch FX, Robles C, Díaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2016;13:119–32
78. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15:565–80
79. Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis 2016;22:56–64
80. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 2015;16:775–86
81. Ogilvie G, Nakisige C, Huh WK, et al. Optimizing secondary prevention of cervical cancer: recent advances and future challenges. Int J Gynecol Obstet 2017;138:15–9
82. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017;17:1293–302
83. Palmer TJ, McFadden M, Pollock KG, et al. HPV immunisation and cervical screening–confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br J Cancer 2016114:582–9. Mar
84. Burger EA, Pedersen K, Sy S, et al. Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway. Br J Cancer 2017117:783–90. Sep
85. Kim JJ, Burger EA, Sy S, et al. Optimal cervical cancer screening in women vaccinated against human papillomavirus. J Natl Cancer Inst 2017;109:djw216
86. Giorgi Rossi P, Carozzi F, Federici A, Italian Screening in HPV vaccinated girls Consensus Conference group, et al. Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference. Prev Med 2017;98:21–30
87. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24:S4–15
88. Klug SJ, Hukelmann M, Blettner M. Knowledge about infection with human papillomavirus: a systematic review. Prev Med 2008;46:87–98
89. Giles M, Garland S. A study of women's knowledge regarding human papillomavirus infection, cervical cancer and human papillomavirus vaccines. Aust N Z J Obstet Gynaecol 2006;46:311–5
90. Hendry M, Pasterfield D, Lewis R, et al. Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing. Br J Cancer 2012;107:243–54
91. Smith L, van Niekerk D, Coldman A, et al. Recommendations for implementing human papillomavirus-based cervical cancer screening: lessons learned from the HPV FOCAL trial. J Obstet Gynaecol Can 2016;38:723–6
92. Ogilvie GS, Smith LW, van Niekerk DJ, et al. Women's intentions to receive cervical cancer screening with primary human papillomavirus testing. Int J Cancer 2013; Dec 15133:2934–43
93. Arbyn M, Xu L, Verdoodt F, et al. Genotyping for HPV16 and HPV18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann Intern Med 2017;166:118–2
94. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013;17:S28–35